beat365Õý°æΨһ¹ÙÍø

¿ÆÑÐЧÀÍ

RESEARCH SERVICES
¿ÆÑÐЧÀÍ
¶ÌÁ´Ö¬·¾Ëá
¶ÌÁ´Ö¬·¾Ëá(ͼ1)²úÆ·¼ò½é

¶ÌÁ´Ö¬·¾Ëá(Short-Chain Fatty Acids, SCFAs)£¬Ò²³Æ»Ó·¢ÐÔÖ¬·¾Ëá(Volatile Fatty Acid, VFA)£¬Æ¾Ö¤Ì¼Á´ÖÐ̼ԭ×ÓÊýÄ¿£¬°Ñ̼ԭ×ÓÊý1-6µÄÓлúÖ¬·¾Ëá³ÆΪ¶ÌÁ´Ö¬·¾ËᣬÖ÷Òª°üÀ¨ÒÒËá¡¢±ûËá¡¢¶¡Ëá¡¢Ò춡Ëá¡¢ÎìËá¡¢ÒìÎìËá¡£
Ö÷ҪȪԴÓڽ᳦ÖÐÑáÑõϸ¾ú¶Ô³¦µÀÄÚÏËάºÍ²»¿ÉÏû»¯Ìǵķ¢½Í£¬ÊÜ·¢½Íµ×Îϸ¾úÖÖÀàµÈÒòËصÄÓ°Ï죬³¦µÀÄÚËù±¬·¢µÄ¶ÌÁ´Ö¬·¾ËáµÄÖÖÀàºÍÊýÄ¿²î±ð£¬ÆäÊ©Õ¹µÄ×÷ÓÃÒ²²»¾¡Ïàͬ¡£×÷Ϊ³¦µÀ΢ÉúÎïµÄÖ÷Òª´úл²úÆ·£¬¾ßÓÐΪ¶¯ÎïÌåÌṩÄÜÁ¿¡¢µ÷ÀíÄÜÁ¿´úл¡¢¼ÓÈëÐźÅתµ¼¡¢¸ÄÉÆÐÄѪ¹Ü¼²²¡¡¢»º½âÌÇÄò²¡²¡Ö¢¡¢Î¬³Ö³¦µÀ´úлÍêÕûÐÔ¡¢µ÷Àí³¦µÀ¾úȺºÍÃâÒß¹¦Ð§µ÷¿ØµÈ¶àÖÖÉúÎïѧ¹¦Ð§¡£
ÔÚÖ²ÎïÌåÄÚ£¬¶ÌÁ´Ö¬·¾ËáÊÇÖ÷ÒªµÄ·çÔÏÎïÖʼ°ÓªÑøÎïÖÊ£¬ÈçÑ̲ݵÄÏãζÖÐÆðÖ÷Òª×÷ÓÃ;ÔÚ¶¯ÎïÖУ¬¶ÌËá¿ÉÒÔÌá¸ßÈÑÉïĸÖíµÄ²ÉʳÁ¿Ó벸ÈéĸÖíµÄÃÚÈéÁ¿£¬½ø¶øÌá¸ßĸÖíµÄÉú²úÐÔÄÜ£¬ÔÚÇà´¢ËÇÁÏÖУ¬ÒÒËáºÍ±ûËáÖ÷Òª±»ÓÃ×÷·À¸¯¼Á¾ÙÐÐÖü´æºÍ±£ÏÊ£¬ÒÒËáµÈ¶ÌÁ´Ö¬·¾ËẬÁ¿Ó°ÏìËÇÁÏÊÊ¿ÚÐÔ¼°Ò×Ïû»¯ÎüÊÕµÄˮƽ¡£

¶ÌÁ´Ö¬·¾Ëá

¶ÌÁ´Ö¬·¾Ëá¼ì²âÁбí

1¶Ô1×Éѯ

¶ÌÁ´Ö¬·¾Ëá(ͼ4)ÊÖÒÕÓÅÊÆ

½ÓÄÉÄڱ귨¶¨Á¿£¬¶¨ÐÔ¶¨Á¿Ð§¹û¸ü×¼

¶ÌÁ´Ö¬·¾Ëá(ͼ3)ÊÖÒÕõ辶

ÊÖÒÕõ辶

¶ÌÁ´Ö¬·¾Ëá(ͼ5)ÊÖÒÕ²ÎÊý

Ñù±¾ÒªÇó
Ö²Îï×éÖ¯£º200 mg/sample
¶¯Îï¼°ÁÙ´²×éÖ¯Ñù±¾£º200 mg/sample
ѪÇ塢Ѫ½¬£º200 ¦ÌL/sample
ÄòÒº£º200 ¦ÌL/sample
ϸ°û¡¢Î¢ÉúÎ1X107cells/sample
·à±ã¡¢³¦µÀÄÚÈÝÎ200 mg/sample

¼ì²âƽ̨
GC-MS QP2020, Shimadzu

ͨÀýÏîÄ¿ÖÜÆÚ
ʵÑé¼ì²â£º20¸ö×ÔÈ»ÈÕ£¨´ÓÊÕµ½¿Í»§Ô¤¸¶¿î²¢ÊÕµ½ÑùÆ·Ö®ÈÕÆð£©
Êý¾ÝÆÊÎö£º5¸ö×ÔÈ»ÈÕ

icon-27.pngÓ¦ÓÃÆ«Ïò
  • icon6.png
    Ò©Îï»ò±£½¡Æ·µÄ¿ª·¢Ñо¿
  • ¿ÆÑÐЧÀÍÍøÕ¾icon-77.png
    ¼²²¡µÄÔçÆÚÕï¶Ï±ê¼ÇÎï·¢Ã÷Ñо¿
  • ¿ÆÑÐЧÀÍÍøÕ¾icon-59.png
    Ö²Îï·çÔÏÑо¿
  • ¿ÆÑÐЧÀÍÍøÕ¾icon-05.png
    ÐóÇÝËÇÁÏÖÐÌí¼Ó
icon-28°¸ÀýÆÊÎö

ÅÁ½ðÉ­²¡»¼Õß·à±ãºÍѪ½¬¶ÌÁ´Ö¬·¾ËáˮƽÓ볦µÀ¾úȺºÍÁÙ´²Ö¸±êµÄ¹Øϵ

Ñо¿¹¤¾ß:                 ÈË

ÆÚ¿¯:                        Neurology

Ó°ÏìÒò×Ó:                 11.8

ʱ¼ä:                        2022Äê

Ñо¿Åä¾°
ÅÁ½ðÉ­²¡(Parkinson's disease, PD)ÊÇÒ»ÖÖ³£¼ûµÄÉñ¾­ÏµÍ³¼²²¡¡£Ñо¿Åú×¢£¬Î¸³¦µÀÖ¢×´¿ÉÄܱÈÔ˶¯Ö¢×´Ô缸ʮÄê¡£Ó뿵½¡ÈËȺÏà±È£¬PD»¼Õß¾ßÓÐÆæÒìµÄ³¦µÀ΢ÉúÎïȺ½á¹¹£¬²¢ÇÒ³¦µÀ΢ÉúÎïȺµÄת±äÓë¼²²¡µÄÑÏÖØˮƽºÍÏ£ÍûÏà¹Ø¡£¶ÌÁ´Ö¬·¾Ëá(Short-Chain Fatty Acids, SCFAs)Êdz¦µÀ¾úȺ·¢½ÍÉÅʳÏËά±¬·¢µÄÖ÷Òª´úлÎÍƲâÔÚ³¦-ÄÔÏ໥×÷ÓÃÖÐÆðÒªº¦×÷Óᣵ«ÏÖÔÚÈÔȱ·¦¹ØÓÚ¼ì²â·à±ãºÍѪ½¬ÖÐSCFAsˮƽµÄ×ÛºÏÑо¿¡£

Ñо¿Ð§¹û
ʹÓÃÆøÏàÉ«Æ×-ÖÊÆ×(Gas Chromatography-Mass Spectrometry, GC-MS)¶Ô·à±ãºÍѪ½¬ÖеÄSCFAs¾ÙÐж¨Á¿ÆÊÎö£¬·¢Ã÷PD»¼Õß·à±ãºÍѪ½¬ÖжÌËá±£´æ²î±ð¡£SCFAsÓëÔ˶¯ÕÏ°­ÑÏÖØˮƽ¡¢ÈÏÖªÄÜÁ¦¡¢³¦µÀ¾úȺ¹ØÁªÆÊÎöÏÔʾ£¬·à±ãÖеÍˮƽSCFAs¡¢Ñª½¬Öиßˮƽ±ûËáÓëPD»¼ÕߵĵÍÔ˶¯ÄÜÁ¦Ïà¹Ø £»·à±ãÖеÍˮƽSCFAs¡¢Ñª½¬Öиßˮƽ¶¡ËáºÍÎìËáÓë½Ï²îµÄÈÏÖªÏà¹Ø £»PD»¼Õß²¿·Ö¾úȺƷòµÄ¸Ä±äÓëѪ½¬ºÍ·à±ãÖÐSCFAsˮƽÏà¹Ø¡£Ð§¹ûÅú×¢£¬SCFAs¿ÉÒÔ×÷Ϊ·´Ó¦PDÑÏÖØˮƽµÄ±ê¼ÇÎÓÐÖúÓÚ½øÒ»²½ÆÊÎöPD»¼ÕßÖØ´óµÄ³¦-ÄÔÏ໥×÷Óá£

Ñо¿Ë¼Ð÷

Ñо¿Ë¼Ð÷

Ч¹ûչʾ
ͨ¹ý¶Ô·à±ãÓëѪ½¬ÖеÄSCFAs¼ì²â£¬·¢Ã÷Óë±ÈÕÕ×éÏà±È£¬PD»¼Õß·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡ËáŨ¶ÈÏÔÖø½µµÍ£¨Í¼1£© £»Ñª½¬ÖбûËá¡¢¶¡ËáºÍÎìËáµÄŨ¶ÈÏÔÖøÔöÌí£¨Í¼2£©¡£

Ч¹ûչʾ

ͨ¹ýROCÇúÏßÆÊÎöÕ¹ÍûPDµÄ±¬·¢£¬·¢Ã÷Ëæ×Å·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡Ëáˮƽ½µµÍ¼°Ñª½¬ÖбûËá¡¢¶¡ËáºÍÎìËáˮƽÔöÌí£¬AUCÕ¹Íû׼ȷ¶ÈÌá¸ß£¨Í¼3A£©¡£±ðµÄ£¬½«·à±ãºÍѪ½¬ÖÐSCFAsˮƽÓëÔ˶¯ÕÏ°­ÑÏÖØˮƽ×ö¹ØÁªÆÊÎö£¬·¢Ã÷·à±ãÖÐÒÒËá¡¢±ûËáºÍ¶¡ËáµÄˮƽÓëÔ˶¯ÄÜÁ¦³Ê¸ºÏà¹Ø¡£

PD»¼ÕßÓë±ÈÕÕ×éµÄROCÆÊÎö¼°PD»¼ÕßÖÐSCFAsˮƽÓëÁÙ´²Ô˶¯Ö¢×´ÑÏÖØˮƽ֮¼äµÄÏà¹ØÐÔ

ͼ3.PD»¼ÕßÓë±ÈÕÕ×éµÄROCÆÊÎö¼°PD»¼ÕßÖÐSCFAsˮƽÓëÁÙ´²Ô˶¯Ö¢×´ÑÏÖØˮƽ֮¼äµÄÏà¹ØÐÔ

ÈÏÖªÕý³£µÄPD»¼Õߺͻ¼ÓгմôÖ¢µÄPD(Parkinson Disease Dementia, PDD)»¼ÕßµÄSCFAs²î±ðÆÊÎöÏÔʾ£¬Ñª½¬ÖУ¬PDD»¼ÕßѪ½¬ÖÐÒ춡ËáºÍÎìËáˮƽÏÔÖøÉý¸ß£¨Í¼4B)£¬ÕâÅúעѪ½¬Ò춡ËáºÍÎìËáˮƽÓëÈÏÖªÄÜÁ¦³Ê¸ºÏà¹Ø¡£

²î±ðÈÏÖªÑÏÖØˮƽµÄPD»¼Õß·à±ãºÍѪ½¬ÖÐSCFAsŨ¶ÈµÄ½ÏÁ¿¼°SCFAsˮƽÓë

ͼ4.²î±ðÈÏÖªÑÏÖØˮƽµÄPD»¼Õß·à±ãºÍѪ½¬ÖÐSCFAsŨ¶ÈµÄ½ÏÁ¿¼°SCFAsˮƽÓëÈÏÖªÄÜÁ¦Ö®¼äµÄÏà¹ØÐÔ

ºê»ùÒò×éÆÊÎöÅú×¢£¬PD»¼ÕߵľúȺ¸»ºñ¶È¸ßÓÚ±ÈÕÕ×飨ͼ5£©¡£½øÒ»²½ÆÊÎö³¦µÀ¾úȺÓëSCFAsµÄÏà¹ØÐÔ£¬Ð§¹ûÅú×¢£¬ÔÚPD»¼ÕßÖУ¬Ò»Ð©Ìض¨³¦µÀ΢ÉúÎïȺºÍPD»¼ÕßÔ˶¯»òÈÏÖªÕÏ°­ÑÏÖØˮƽÏà¹ØµÄSCFA¾ßÓÐÏà¹ØÐÔ¡£

Ч¹ûչʾ4

²Î¿¼ÎÄÏ×
Chen Szu-Ju,Chen Chieh-Chang,Liao Hsin-Yu et al. Association of Fecal and Plasma Levels of  Short-Chain Fatty Acids With Gut Microbiota and Clinical Severity in Parkinson Disease Patients.[J] .Neurology,  2022.

Ãâ·ÑÉêÇëGC-MS·Ç°Ð±ê´úл×éѧ

΢ÐÅ

ÔÚÏß
×Éѯ

QQ

µã»÷QQ×Éѯ

·µ»Ø
¶¥²¿

¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿